LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Imatinib | 10.0 | uM | LJP6 | 2 | N13 | 72 | hr | 1657 | 5448 | 5505 | 0.9895 | 0.9850 |
| BT-20 | Imatinib | 10.0 | uM | LJP6 | 3 | N13 | 72 | hr | 1657 | 5206 | 5505 | 0.9456 | 0.9221 |
| BT-20 | JNK-9L | 10.0 | uM | LJP6 | 1 | K19 | 72 | hr | 1657 | 1281 | 5505 | 0.2327 | -0.0979 |
| BT-20 | JNK-9L | 10.0 | uM | LJP6 | 2 | K19 | 72 | hr | 1657 | 1149 | 5505 | 0.2087 | -0.1322 |
| BT-20 | JNK-9L | 10.0 | uM | LJP6 | 3 | K19 | 72 | hr | 1657 | 1310 | 5505 | 0.2379 | -0.0904 |
| BT-20 | JW-7-24-1 | 10.0 | uM | LJP6 | 1 | B19 | 72 | hr | 1657 | 1685 | 5505 | 0.3061 | 0.0071 |
| BT-20 | JW-7-24-1 | 10.0 | uM | LJP6 | 2 | B19 | 72 | hr | 1657 | 1914 | 5505 | 0.3476 | 0.0666 |
| BT-20 | JW-7-24-1 | 10.0 | uM | LJP6 | 3 | B19 | 72 | hr | 1657 | 1842 | 5505 | 0.3346 | 0.0479 |
| BT-20 | Lapatinib | 10.0 | uM | LJP6 | 1 | M19 | 72 | hr | 1657 | 4356 | 5505 | 0.7912 | 0.7012 |
| BT-20 | Lapatinib | 10.0 | uM | LJP6 | 2 | M19 | 72 | hr | 1657 | 4290 | 5505 | 0.7792 | 0.6841 |
| BT-20 | Lapatinib | 10.0 | uM | LJP6 | 3 | M19 | 72 | hr | 1657 | 4112 | 5505 | 0.7469 | 0.6378 |
| BT-20 | LDN-193189 | 10.0 | uM | LJP5 | 1 | G01 | 72 | hr | 1657 | 463 | 5505 | 0.0841 | -0.3105 |
| BT-20 | LDN-193189 | 10.0 | uM | LJP5 | 2 | G01 | 72 | hr | 1657 | 566 | 5505 | 0.1028 | -0.2837 |
| BT-20 | LDN-193189 | 10.0 | uM | LJP5 | 3 | G01 | 72 | hr | 1657 | 608 | 5505 | 0.1104 | -0.2728 |
| BT-20 | Linifanib | 10.0 | uM | LJP6 | 1 | J07 | 72 | hr | 1657 | 2890 | 5505 | 0.5249 | 0.3202 |
| BT-20 | Linifanib | 10.0 | uM | LJP6 | 2 | J07 | 72 | hr | 1657 | 2935 | 5505 | 0.5331 | 0.3319 |
| BT-20 | Linifanib | 10.0 | uM | LJP6 | 3 | J07 | 72 | hr | 1657 | 2808 | 5505 | 0.5100 | 0.2989 |
| BT-20 | Linsitinib | 10.0 | uM | LJP5 | 1 | O19 | 72 | hr | 1657 | 4636 | 5505 | 0.8420 | 0.7740 |
| BT-20 | Linsitinib | 10.0 | uM | LJP5 | 2 | O19 | 72 | hr | 1657 | 4478 | 5505 | 0.8133 | 0.7329 |
| BT-20 | Linsitinib | 10.0 | uM | LJP5 | 3 | O19 | 72 | hr | 1657 | 4060 | 5505 | 0.7374 | 0.6243 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 1657 | 957 | 5505 | 0.1738 | -0.1821 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 1657 | 920 | 5505 | 0.1671 | -0.1917 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 1657 | 1264 | 5505 | 0.2296 | -0.1023 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 1657 | 762 | 5505 | 0.1384 | -0.2328 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 1657 | 1020 | 5505 | 0.1853 | -0.1657 |